New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

April 2017

Welcome to the April 2017 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the April issue!

The PharmSource Team

 

PharmSource Coverage of AACR 2017 Yields Valuable BD Info

by Brooke Wilson, Senior Research Analyst

You might have noticed it was a busy week on the PharmSource Lead Sheet. The beginning of April found myself and fellow Research Analyst, Mahdia Hashimy, covering the 2017 American Association for Cancer Research (AACR) conference in Washington DC. Here we gathered all the latest news and early research data in the oncology field from researchers from around the world.

There was so much to report that 55% of our pipeline leads for the Lead Sheet Drug Edition for the Week of April 6th were in the oncology field, with 70% of these in Preclinical or Phase I… read on
 

PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity

Lead Type March 2017 YTD 2017
Early Development 90 304
Late Development 85 309
Biologic 85 291
Small Molecule 201 700
Parenteral 93 318
Oral 79 267
New Financings 104 248
Total Drug Leads 344 1052
Total Device &
Diagnostic Leads
147 428

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


 

Pipeline Tip

Intezyne Technologies plans to initiate a Phase Ib/IIa trial in early 2018 with IT-139, a novel GRP78 inhibitor, for the treatment of solid tumors:

  • Therapeutic Area: Oncology – Other
  • Dosage Form: Parenteral – Lyophilized
  • API: Chemical – Normal potency

Get deeper information about the likely upcoming needs of Intezyne, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.
 

Look out! Zika!

by Scotty Chung-Siu, Research Analyst

The Zika virus has become a global concern since its epidemic in 2015-2016. During that time, on February 26, 2016, Sylvia Burwell of the US Health and Human Services declared the authorization of emergency use of in vitro diagnostics for the detection and diagnosis of the Zika virus.

According to the PharmSource Lead Sheet: Device & Diagnostics Edition, since February 2016, there have been 14 diagnostic tests that have been granted FDA Emergency Use Authorization with two more currently… read on
 

Follow the Money to

Bio/Pharmaceutical Opportunities

Spotlight on BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals is a U.S. public bio/pharmaceutical company that discovers drugs for the treatment of infectious diseases, inflammatory diseases and cancer. They raised $45 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds for future clinical development of BCX7353, for continued development of its second-generation compounds for HAE and… read on
 
 

Follow the Money to

Medical Device & Diagnostic Opportunities

Spotlight on RenalGuard Solutions, Inc.

RenalGuard Solutions is a U.S. private company that develops cardiac and vascular technologies. They raised $14.5 million in the completion of a Series A venture capital investment.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support the pivotal clinical trial of the RenalGuard System… read on
 

M&A in the CMC Services Industry: Implications and Outlook

PharmSource’s just-released trend report, M&A in the CMC Services Industry: Implications and Outlook, analyzes how M&A in the bio/pharma contract services industry is likely to play out over the next two years. Key questions it addresses include:

1. Which capabilities are likely to be most in demand by acquirers?

2. Which companies are likely to be the most active acquirers?

3. What developments would most likely slow M&A activity?


 

PharmSource Lead Sheet

The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

See for yourself how this resource can be a vital tool for building your brand and growing your market share.

To request a test-drive today, contact Nathaniel Celentano at nathaniel@pharmsource.com / 1-703-383-4903, ext. 112 (ET USA).